AI may soon predict your breast cancer treatment success
NCT ID NCT05981326
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is collecting medical data, blood samples, and lifestyle information from 300 people with early breast cancer. The goal is to create a computer algorithm that can predict whether a patient will have a complete response to chemotherapy before they start treatment. This is not a treatment trial but a research project to improve personalized medicine.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a computer tool that helps doctors predict which breast cancer treatments will work best for each patient, improving outcomes.
- What could go wrong
- This is an early observational study, not testing a treatment. The algorithm may not be accurate enough for real-world use, and results may take years to validate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2023
- Expected to finish
-
Apr 2033
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening biopsy, blood samples and questionnaires 2. 18 years old or at time of written consent 3. Patient with histologically confirmed breast cancer 4. Absence of metastatic disease 5. Patient requiring neoadjuvant chemotherapy 6. Performance status ≤ 2 (according to WHO criteria) 7. Indication of any systemic therapeutic strategy can be performed alongside this current cohort in accordance with national and / or international recommendations. 8. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up. 9. Patient must be affiliated to a Social Health Insurance 10. For patients taking part in the RTW WP: working patients at time of diagnostic and in sick leave at time of inclusion Exclusion Criteria: 1. Other malignancy treated within the last 5 years (except non-melanoma skin cancer or in situ carcinoma of the cervix) 2. Non epithelial breast cancer 3. Coagulopathy or other pathology that contraindicates biopsy procedures 4. Pregnant or nursing patient 5. Individual deprived of liberty or placed under the authority of a tutor 6. Impossibility to submit to the medical follow-up of this clinical trial for geographical, social or psychological reasons 7. For patients taking part in the RTW WP: patient in an "self employed" or "interim" employment situation 8. For patients taking part in the RTW WP: Patients working part-timeProcedures for withdrawal of incorrectly enrolled patients are presented in Section 7.5.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Institut de Cancérologie de l'Ouest
RECRUITINGAngers, 49055, France
-
Institut de Cancérologie de l'Ouest
RECRUITINGSaint-Herblain, 44805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?
- Can a Decades-Old Anti-Inflammatory drug quiet the joint pain that drives women off breast cancer therapy?